Does polymorphysm of genes coding for pro-inflammatory mediators predict the clinical response to tnf alpha blocking agents? A review analysis of the literature

Francesca Ingegnoli, Ennio Giulio Favalli, Pier Luigi Meroni

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Tumor necrosis factor-α (TNF-α) has a key role in the pathogenesis of rheumatoid arthritis (RA) and the introduction of anti-TNFα biological therapies has dramatically altered the treatment of RA. Anti-TNFα agents display good clinical efficacy in patients resistant to traditional disease-modifying antirheumatic drugs and superior efficacy in the suppression of erosive joint damage, even if a significant non-response rate has been reported (30-40%). Because anti-TNFα therapy is associated with expensive treatment costs, leading to restrictions in the numbers of patients who may be treated, the identification of predictors of treatment outcome may improve the cost-effectiveness of anti-TNFα therapies. Several candidate gene studies have addressed this topic, but they have had limited success in identifying predictors. It is not clear whether the response to anti-TNFα treatment will be conferred through a number of genes, each with a small effect size, or whether genes may predict the outcome of the treatment.

Original languageEnglish
Pages (from-to)460-463
Number of pages4
JournalAutoimmunity Reviews
Volume10
Issue number8
DOIs
Publication statusPublished - Jun 2011

Fingerprint

Genes
Rheumatoid Arthritis
Biological Therapy
Antirheumatic Agents
Therapeutics
Health Care Costs
Cost-Benefit Analysis
Tumor Necrosis Factor-alpha
Joints

Keywords

  • Anti-TNFα blockers
  • Polymorphism
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Does polymorphysm of genes coding for pro-inflammatory mediators predict the clinical response to tnf alpha blocking agents? A review analysis of the literature. / Ingegnoli, Francesca; Favalli, Ennio Giulio; Meroni, Pier Luigi.

In: Autoimmunity Reviews, Vol. 10, No. 8, 06.2011, p. 460-463.

Research output: Contribution to journalArticle

@article{af0f023f99424732995978e855446a27,
title = "Does polymorphysm of genes coding for pro-inflammatory mediators predict the clinical response to tnf alpha blocking agents? A review analysis of the literature",
abstract = "Tumor necrosis factor-α (TNF-α) has a key role in the pathogenesis of rheumatoid arthritis (RA) and the introduction of anti-TNFα biological therapies has dramatically altered the treatment of RA. Anti-TNFα agents display good clinical efficacy in patients resistant to traditional disease-modifying antirheumatic drugs and superior efficacy in the suppression of erosive joint damage, even if a significant non-response rate has been reported (30-40{\%}). Because anti-TNFα therapy is associated with expensive treatment costs, leading to restrictions in the numbers of patients who may be treated, the identification of predictors of treatment outcome may improve the cost-effectiveness of anti-TNFα therapies. Several candidate gene studies have addressed this topic, but they have had limited success in identifying predictors. It is not clear whether the response to anti-TNFα treatment will be conferred through a number of genes, each with a small effect size, or whether genes may predict the outcome of the treatment.",
keywords = "Anti-TNFα blockers, Polymorphism, Rheumatoid arthritis",
author = "Francesca Ingegnoli and Favalli, {Ennio Giulio} and Meroni, {Pier Luigi}",
year = "2011",
month = "6",
doi = "10.1016/j.autrev.2011.01.010",
language = "English",
volume = "10",
pages = "460--463",
journal = "Autoimmunity Reviews",
issn = "1568-9972",
publisher = "Elsevier",
number = "8",

}

TY - JOUR

T1 - Does polymorphysm of genes coding for pro-inflammatory mediators predict the clinical response to tnf alpha blocking agents? A review analysis of the literature

AU - Ingegnoli, Francesca

AU - Favalli, Ennio Giulio

AU - Meroni, Pier Luigi

PY - 2011/6

Y1 - 2011/6

N2 - Tumor necrosis factor-α (TNF-α) has a key role in the pathogenesis of rheumatoid arthritis (RA) and the introduction of anti-TNFα biological therapies has dramatically altered the treatment of RA. Anti-TNFα agents display good clinical efficacy in patients resistant to traditional disease-modifying antirheumatic drugs and superior efficacy in the suppression of erosive joint damage, even if a significant non-response rate has been reported (30-40%). Because anti-TNFα therapy is associated with expensive treatment costs, leading to restrictions in the numbers of patients who may be treated, the identification of predictors of treatment outcome may improve the cost-effectiveness of anti-TNFα therapies. Several candidate gene studies have addressed this topic, but they have had limited success in identifying predictors. It is not clear whether the response to anti-TNFα treatment will be conferred through a number of genes, each with a small effect size, or whether genes may predict the outcome of the treatment.

AB - Tumor necrosis factor-α (TNF-α) has a key role in the pathogenesis of rheumatoid arthritis (RA) and the introduction of anti-TNFα biological therapies has dramatically altered the treatment of RA. Anti-TNFα agents display good clinical efficacy in patients resistant to traditional disease-modifying antirheumatic drugs and superior efficacy in the suppression of erosive joint damage, even if a significant non-response rate has been reported (30-40%). Because anti-TNFα therapy is associated with expensive treatment costs, leading to restrictions in the numbers of patients who may be treated, the identification of predictors of treatment outcome may improve the cost-effectiveness of anti-TNFα therapies. Several candidate gene studies have addressed this topic, but they have had limited success in identifying predictors. It is not clear whether the response to anti-TNFα treatment will be conferred through a number of genes, each with a small effect size, or whether genes may predict the outcome of the treatment.

KW - Anti-TNFα blockers

KW - Polymorphism

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=79957665365&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79957665365&partnerID=8YFLogxK

U2 - 10.1016/j.autrev.2011.01.010

DO - 10.1016/j.autrev.2011.01.010

M3 - Article

VL - 10

SP - 460

EP - 463

JO - Autoimmunity Reviews

JF - Autoimmunity Reviews

SN - 1568-9972

IS - 8

ER -